Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITIOUS phase II study of atezolizumab in advanced or recurrent non-small cell lung cancer with idiopathic interstitial pneumonia
jRCTs031190084Phase 2Completed
- Sponsor
- Japan Thoracic Oncology Research Group
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC) and idiopathic interstitial pneumonia (IIP), sponsored by Japan Thoracic Oncology Research Group. Primary endpoint: 1-year survival rate. Started Sep 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)idiopathic interstitial pneumonia (IIP)
Beyond the preview
Go deeper on jRCTs031190084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190084.